Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Conditions

Myasthenia Gravis 3Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

rozanolixizumab 5zilucoplan 4eculizumab 4Rituximab 4Immunoglobulins, Intravenous 4efgartigimod alfa 3Tacrolimus 3Mycophenolic Acid 3Hizentra 3HBM9161 3Data Collection 2Azathioprine 2tofacitinib 1telitacicept 1ravulizumab 1iscalimab 1gamma-Globulins 1apraclonidine 1Thymectomy 1Telemedicine 1Sugammadex 1Sodium Chloride 1Pyridostigmine Bromide 1Prednisone 1Prednisolone 1Plasmapheresis 1Plasma Exchange 1Neurofeedback 1Neostigmine 1Muscle Stretching Exercises 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Myasthenia Gravis × Hizentra × Clear all
NCT04728425 2025-04-27

MG_SCIG

University Health Network, Toronto

Phase 2 Completed
30 enrolled

Myasthenia Gravis

NCT02774239 2023-02-21

SCIG-MG

University of Alberta

Phase 3 Completed
26 enrolled

Myasthenia Gravis

NCT02100969 2021-06-02

Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

University of Kansas Medical Center

Phase 2 Completed
23 enrolled 18 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡